Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Trading 12-11 15:02:16 EST

1.50

+0.01

+0.34%

High1.53	Low1.46	Vol124.04K
Open1.50	D1 Closing1.49	Amplitude4.36%
Mkt Cap62.60M	Tradable Cap52.24M	Total Shares41.88M
T/O186.06K	T/O Rate0.35%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.495,"timestamp":1765483268772,"preClose":1.49,"halted":0,"volume":124039,"delay":0,"floatShares":34944200,"shares":41876087,"eps":-1.611899,"marketStatus":"Trading","change":0.005,"latestTime":"12-11 15:02:16 EST","open":1.5,"high":1.525,"low":1.46,"amount":186057.17278269998,"amplitude":0.043624,"askPrice":1.5,"askSize":11596,"bidPrice":1.49,"bidSize":1700,"shortable":3,"etf":0,"ttmEps":-1.611899,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.49,"preHourTrading":{"tag":"盘前","latestPrice":1.436,"preClose":1.49,"latestTime":"08:46 EST","volume":88,"amount":126.01599999999999,"timestamp":1765460771980},"postHourTrading":{"tag":"盘后","latestPrice":1.41,"preClose":1.49,"latestTime":"17:43 EST","volume":1722,"amount":2542.474,"timestamp":1765406623219},"volumeRatio":0.823643},"requestUrl":"/m/hq/s/MIRA","defaultTab":"news","newsList":[{"id":"2583046593","title":"Mira Pharmaceuticals Q3 EPS $(1.18) Misses $(0.08) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583046593","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583046593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:50","pubTimestamp":1763041807,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(0.08) by 1375 percent. This is a 742.86 percent decrease over losses of $(0.14) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48832547/mira-pharmaceuticals-q3-eps-1-18-misses-0-08-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2577530523","title":"BRIEF-Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577530523","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577530523?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:38","pubTimestamp":1761259087,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC FilingOct 24  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - INITIATES PHASE 1 STUDY OF KETAMIR-2 - SEC FILINGSource text: [ID:n0001493152-25-019065]Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nFWN3W436K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2577318255","title":"MIRA Pharmaceuticals Advances Ketamir-2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2577318255","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577318255?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:40","pubTimestamp":1761252003,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) phase of its Ph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-advances-ketamir-2-clinical-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-advances-ketamir-2-clinical-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2577816535","title":"Mira Pharmaceuticals Launches Phase 1 Trial of Oral Ketamir-2 for Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2577816535","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577816535?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:02","pubTimestamp":1761249755,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced the initiation of the multiple ascending dose  portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. The company has also selected chemotherapy-induced peripheral neuropathy  as the lead indication for its planned Phase 2a trial. The Phase 1 study is randomized, double-blind, and placebo-controlled, assessing the safety, tolerability, and pharmacokinetics of Ketamir-2. No serious or dose-limiting adverse events have been observed to date, and no clinically significant safety concerns have been reported. Results from the comprehensive pharmacokinetic analyses will be presented following unblinding. Ketamir-2 is a novel oral analog of ketamine developed to address limitations of current therapies and is being considered for further development in CIPN due to the lack of FDA-approved treatments for this condition.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL8bRsL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576755467","title":"MIRA Pharmaceuticals Sells Shares at 66% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2576755467","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576755467?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:37","pubTimestamp":1760647027,"startTime":"0","endTime":"0","summary":"The latest announcement is out from MIRA Pharmaceuticals, Inc. ( ($MIRA) ). On October 16, 2025, MIRA Pharmaceuticals, Inc. sold 1,751,000 shares o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-sells-shares-at-66-premium?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-sells-shares-at-66-premium?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576786037","title":"Mira Pharmaceuticals Inc - Sells 1,751,000 Shares at $2.19 Each - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2576786037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576786037?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:04","pubTimestamp":1760645042,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VX2NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2576778680","title":"Mira Pharmaceuticals Raises $3.8 Million Through Block Sale of 1.75 Million Shares at 66% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2576778680","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576778680?lang=en_us&edition=fundamental","pubTime":"2025-10-17 04:02","pubTimestamp":1760644957,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced the sale of 1,751,000 shares of its common stock to multiple institutional investors through a block sale. The shares were sold at an average price of $2.19 each, representing a 66% premium to the previous day's closing price. The transaction, facilitated by Rodman & Renshaw via the StockBlock platform, generated gross proceeds of approximately $3.84 million before fees and expenses. No warrants were included in the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Octo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL5SbylZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2576333722","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2576333722","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576333722?lang=en_us&edition=fundamental","pubTime":"2025-10-17 02:22","pubTimestamp":1760638967,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) said two phase 3 trials of its investigational drug ulixacaltamide in essential tremor met primary and secondary endpoints.Shares surged nearly 200% as intraday tradi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MIRA","APLM","PRAX","BK4139","BK4007"],"gpt_icon":0},{"id":"2575725898","title":"BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Praxis, Snowflake","url":"https://stock-news.laohu8.com/highlight/detail?id=2575725898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575725898?lang=en_us&edition=fundamental","pubTime":"2025-10-16 23:51","pubTimestamp":1760629913,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Praxis, SnowflakeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX0XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFIV","FOSL","AEP","PSNL","LU0321505439.SGD","JBHT","LU1633808545.USD","MIRA","JACK","HPE","DFLI","AIG","IE00BZ1G4Q59.USD","PRU","SATL","TMO","ZION","MMC","LU0251142724.SGD","SNA","DASH","IE00BKPKM429.USD","WAL","IE0002270589.USD","LU0251132253.USD","GRAL","LU1778281490.HKD","SCHW","VERI","LU0122379950.USD","BK4007","HYPR","LU1983299246.USD","UAL","BG","SNOW","TMUS","LU0251131958.USD","NEM","PRAX","TRV","CMC","LU1935042488.USD","KEY"],"gpt_icon":1},{"id":"2575728393","title":"BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575728393","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575728393?lang=en_us&edition=fundamental","pubTime":"2025-10-16 22:58","pubTimestamp":1760626683,"startTime":"0","endTime":"0","summary":"BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal studyUpdates** Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 52.3% to $2.01, nearly one-year high** Late on Wednesday, company said its experimental oral drug, Mira-55, eased pain and reduced swelling better than injected morphine in a pre-clinical animal study for chronic inflammatory pain** Mira-55 brought pain levels back to normal and directly reduced inflammation by targeting the CB2 receptor - MIRA** CB2 receptors are expressed in immune cells and are involved in the regulation of immune responses and inflammation** Company says morphine only partially reduced inflammation** Data supports marketing application plans for Mira-55 for chronic inflammatory pain - MIRA** Including session's move, shares up ~75% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL3N3VX163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2575742169","title":"BUZZ-Becton falls on CFO exit, preliminary Q4 revenue miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2575742169","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575742169?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:58","pubTimestamp":1760623119,"startTime":"0","endTime":"0","summary":"BUZZ-Becton falls on CFO exit, preliminary Q4 revenue miss** Medical device maker Becton Dickinson's BDX.N shares fall 2.7% to $181.78 during market open** Co's CFO Chris DelOrefice to leave on December 5 to pursue new opportunity; search for permanent successor underway** Co names Vitor Roque, senior VP of finance, interim CFO ** BDX says vaccine-related devices and academic research demand were weaker than expected** Co reports preliminary Q4 revenue of $5.9 billion vs analysts' estimate of $5.91 billion - data compiled by LSEG ** RBC analysts say preliminary results came in slightly below the low end of the company's outlook** Brokerage J.P.Morgan says challenges in Pharma Systems and Biosciences have continued to be less transient than hoped for** Including session moves, stock down ~18% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL3N3VX0JS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820562030.AUD","LU0820561909.HKD","LU1670628061.USD","BK4550","LU0320765646.SGD","LU1244550494.USD","LU1854104046.USD","BK4082","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","LU0234572021.USD","LU0417517546.SGD","LU0345770308.USD","LU1489326972.SGD","LU2381873111.SGD","LU1162221912.USD","IE00BFXG1179.USD","LU0820561818.USD","LU1084165304.USD","LU2054465674.USD","LU1571399168.USD","LU1145028129.USD","LU0130103400.USD","LU0266013472.USD","LU0976567544.SGD","LU2430703251.USD","LU1974910355.USD","LU2552382058.USD","LU0511384066.AUD","LU1244550221.USD","BDX","MIRA","IE000M9KFDE8.USD","LU2552382215.SGD","LU1496350171.SGD","LU0238689110.USD","IE00BN8TJ469.HKD","LU2023250330.USD","LU1670627923.USD","LU0683600562.USD","LU1496350502.SGD","LU1201861165.SGD","LU0648000940.SGD","LU0882574139.USD","LU1548497426.USD","LU0289739343.SGD","LU2430703178.SGD","LU0149725797.USD","IE00BJLML261.HKD","LU0170899867.USD"],"gpt_icon":0},{"id":"2575741918","title":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-Mobile","url":"https://stock-news.laohu8.com/highlight/detail?id=2575741918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575741918?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:11","pubTimestamp":1760620298,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, Fossil Group, T-MobileEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nL6N3VX0LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRV","NIO.SI","EVS.SI","LU0251131958.USD","FOSL","JACK","CMC","LU0976567544.SGD","TMO","TMUS","IE00B7SZLL34.SGD","LU1316542783.SGD","BK4161","GRAL","LU0130102774.USD","LU1023059493.AUD","SNA","PRAX","LU0496367417.USD","BK4168","LU1814569148.SGD","JBHT","LU1506573853.SGD","BK4598","LU1046421795.USD","LU0198837287.USD","AU","AEP","DFLI","SATL","BK4589","MIRA","UAL","IE00B29SXL02.USD","KEY","LU0642271901.SGD","HPE","LU1066051225.USD","NEM","BK4570","LU0128525929.USD","SCHW","SG9999001143.SGD","HYPR","LU0106261372.USD","LU0689472784.USD"],"gpt_icon":1},{"id":"2575743673","title":"Mira Pharmaceuticals announces preclinical data on oral Mira-55","url":"https://stock-news.laohu8.com/highlight/detail?id=2575743673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575743673?lang=en_us&edition=fundamental","pubTime":"2025-10-16 19:40","pubTimestamp":1760614817,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outper...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-oral-mira-55-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-preclinical-data-on-oral-mira-55-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2575124087","title":"Mira Pharmaceuticals Shares up 75.7% Premarket After Co's Experimental Oral Pain Drug Outperforms Morphine in Animal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575124087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575124087?lang=en_us&edition=fundamental","pubTime":"2025-10-16 18:31","pubTimestamp":1760610716,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nFWN3VW2WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2575999537","title":"Why Mira Pharmaceuticals Shares Rose 69% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2575999537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575999537?lang=en_us&edition=fundamental","pubTime":"2025-10-16 13:15","pubTimestamp":1760591700,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals shares surged 68.94% in after-hours trading after the company reported promising preclinical results for its pain treatment candidate, Mira-55.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/16/Stock-Graph-With-Green-Candle-Spike.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/16/Stock-Graph-With-Green-Candle-Spike.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48242497/why-mira-pharmaceuticals-shares-rose-69-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/10/48242497/why-mira-pharmaceuticals-shares-rose-69-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2575751625","title":"MIRA Pharmaceuticals’ Mira-55 Outperforms Morphine in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2575751625","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575751625?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:33","pubTimestamp":1760560433,"startTime":"0","endTime":"0","summary":"The latest announcement is out from MIRA Pharmaceuticals, Inc. ( ($MIRA) ). On October 15, 2025, MIRA Pharmaceuticals announced that its oral Mira-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-mira-55-outperforms-morphine-in-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-mira-55-outperforms-morphine-in-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA"],"gpt_icon":0},{"id":"2575756665","title":"Mira Pharmaceuticals' Oral Mira-55 Outperforms Morphine in Pain Relief and Inflammation Reduction, Preclinical Study Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2575756665","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575756665?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:02","pubTimestamp":1760558555,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced new preclinical research results for its proprietary non-psychotropic marijuana analog, Mira-55. According to the company, oral administration of Mira-55 fully normalized pain and significantly reduced inflammation in an established animal model of chronic inflammatory pain, outperforming injected morphine. The study is notable as the first in the Mira-55 program to directly measure both pain and inflammation. Mira-55, administered orally, restored pain thresholds to baseline levels and showed a direct CB2-receptor-mediated anti-inflammatory effect, whereas morphine provided only partial and indirect inflammation reduction. These findings support Mira Pharmaceuticals' plans to pursue an Investigational New Drug  application for treating chronic inflammatory pain. The announcement does not specify if or when these results will be presented at a scientific conference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL6H7Tnn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2572634005","title":"Telomir Pharmaceuticals Files Initial Beneficial Ownership Statement Listing Mira Pharmaceuticals as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2572634005","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572634005?lang=en_us&edition=fundamental","pubTime":"2025-10-04 08:00","pubTimestamp":1759536058,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has filed an initial statement of beneficial ownership, naming Mira Pharmaceuticals, Inc. as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251004:nNDLbf6YFh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA","TELO"],"gpt_icon":0},{"id":"2571234484","title":"MIRA Pharmaceuticals Completes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with New Obesity and Nicotine Addiction Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2571234484","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571234484?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:30","pubTimestamp":1759231820,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Completes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with New Obesity and Nicotine Addiction Drug Candidate. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on September 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL5Psq73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2571349455","title":"Mira Pharmaceuticals Completes SKNY Acquisition via Stock Exchange and Conducts Multiple At-the-Market Share Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349455","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349455?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230054,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. completed the acquisition of SKNY Pharmaceuticals Inc. on September 29, 2025, issuing restricted shares of Mira common stock to SKNY shareholders in exchange for 100% of SKNY. The number of shares issued was determined by an exchange ratio based on independent third-party valuations of both companies. The specific number of shares and the price per share were not disclosed in the filing. Shares were issued under exemptions provided by Section 4 of the Securities Act of 1933 and Rule 506. Additionally, Mira executed multiple at-the-market stock offering transactions, but details on the number of shares and transaction prices were not provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL3p6sXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.0347},{"period":"1month","weight":0.0205},{"period":"3month","weight":-0.1024},{"period":"6month","weight":0.2314},{"period":"1year","weight":0.192},{"period":"ytd","weight":0.307}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction